Ability to faithfully report drug-target interactions constitutes a major critical parameter in preclinical/clinical settings. Yet the assessment of target engagement remains challenging, particularly for promiscuous and/or polypharmacologic ligands. Drawing from our improved insights into native electrophile signaling and emerging technologies that profile and interrogate these non-enzyme-assisted signaling subsystems, we posit that ‘trained’ polypharmocologic covalent inhibitors can be designed. Accumulating evidence indicates that electrophile-modified states at fractional occupancy can alter cell fate. Thus, by understanding sensing preferences and ligandable regions favored by the natural electrophilic signals at individual protein–lig...
Success stories in drug discovery are mostly circumscribed to traditional targets that often have en...
The quest for “magic bullets” has been the driving force in drug discovery during the last two decad...
Improvements in drug design have historically been centered around structure-based optimization of m...
For several years, drugs with reactive electrophilic appendages have been developed. These units typ...
Revolutionary proteomic strategies have enabled rapid profiling of the cellular targets of electroph...
Interests in learning how to engineer most effective covalent ligands, identify novel functional tar...
Interests in learning how to engineer most effective covalent ligands, identify novel functional tar...
Targeted covalent drugs have recently become integral parts of drug discovery. Given the advantages ...
Covalent drugs have garnered intense interest due to the unique ways in which they can modulate prot...
Covalent drugs have garnered intense interest due to the unique ways in which they can modulate prot...
The ability of target proteins to bind structurally diverse compounds and compounds with different d...
Protein–protein interactions (PPIs) are intriguing targets in drug discovery and development. Peptid...
The quest for “magic bullets” has been the driving force in drug discovery during the last two decad...
Targeting the ubiquitin-proteasome system (UPS) and ubiquitin-like signalling systems (UBL) has been...
Success stories in drug discovery are mostly circumscribed to traditional targets that often have en...
Success stories in drug discovery are mostly circumscribed to traditional targets that often have en...
The quest for “magic bullets” has been the driving force in drug discovery during the last two decad...
Improvements in drug design have historically been centered around structure-based optimization of m...
For several years, drugs with reactive electrophilic appendages have been developed. These units typ...
Revolutionary proteomic strategies have enabled rapid profiling of the cellular targets of electroph...
Interests in learning how to engineer most effective covalent ligands, identify novel functional tar...
Interests in learning how to engineer most effective covalent ligands, identify novel functional tar...
Targeted covalent drugs have recently become integral parts of drug discovery. Given the advantages ...
Covalent drugs have garnered intense interest due to the unique ways in which they can modulate prot...
Covalent drugs have garnered intense interest due to the unique ways in which they can modulate prot...
The ability of target proteins to bind structurally diverse compounds and compounds with different d...
Protein–protein interactions (PPIs) are intriguing targets in drug discovery and development. Peptid...
The quest for “magic bullets” has been the driving force in drug discovery during the last two decad...
Targeting the ubiquitin-proteasome system (UPS) and ubiquitin-like signalling systems (UBL) has been...
Success stories in drug discovery are mostly circumscribed to traditional targets that often have en...
Success stories in drug discovery are mostly circumscribed to traditional targets that often have en...
The quest for “magic bullets” has been the driving force in drug discovery during the last two decad...
Improvements in drug design have historically been centered around structure-based optimization of m...